117 results about "BORATE BUFFER" patented technology

Disclosed is a medical device having an elastic modulus of 100 kPa or more and 2,000 kPa or less, a water content of 10% by mass or less, a tensile elongation of 50% or more and 3,000% or less, and a dynamic contact angle (advancing angle) relative to a borate buffer of 80° or less. The present invention can significantly reduce or avoid a phenomenon of adhesion to a surface when contacted with a surface outside or inside the body, which has hitherto been regarded as a problem in a conventional medical device.

A blood cell analyzer diluent and a hemolytic agent, are characterized in that one litre diluent is provided with 12.0-4.0g of sodium chloride, 2.0-10.0g of sodium sulfate, 0.8-0.5g of 1,3,2-methylol urea, 0.2-0.5g of copper sulfite, 3.0-8.0g of EDTA-2Na, 0.2-0.7g of Piperacillin Sodium, a borate buffering liquid toning the ph value to 7.2-7.8, and the balance is water; one litre hemolytic agent is provided with 0.8-5.0g of potassium chloride, 0-60.0g of dodecyl trimethyl ammonium chloride, 14.0-0g of octadecyl trimethyl ammonium bromide, 6.0-10.0ml of isopropanol, carbonate or alcaine buffering liquid toning the ph value to 7.2-7.8, and the balance is water. The inventive reagent can form stable hemoglobin derivatives, and the absorption spectrum curves are similar when lambada is 540nm, lambada is 504nm, which can satisfy the clinical inspection requirement; the reagent does not contain cyanide, azide, and has non-toxicity, which can effective improve working atmosphere of operating staff, and can reduce harm of toxicant to personal health.

The invention relates to a fluorescent nanometer molecular imprinting biomimetic sensor, a preparation method and applications thereof. The preparation method comprises: weighing carbon quantum dot powder, ultrasonically dispersing in a borate buffer solution, sequentially adding 1-ethyl-(3-(dimethylamino)propyl)carbodiimide hydrochloride and N-hydroxysuccinimide, carrying out a stirring reactionat a room temperature under a dark condition, adding 4-vinylaniline, continuously carrying out the stirring reaction, carrying out dialysis on the obtained product in water, and carrying out freeze drying to obtain surface double bond functionalized carbon quantum dots; adding a template molecule and two different functional monomers to a pore forming agent, ultrasonically dissolving, and carryingout stirring pre-polymerization at a room temperature to obtain a pre-assembly solution A; ultrasonically dispersing the surface double bond functionalized carbon quantum dots in a pore forming agentto obtain a solution B; uniformly mixing the solution A and the solution B, adding a cross-linking agent and an initiator, introducing nitrogen, stirring, carrying out centrifugation, collecting theprecipitate, and washing with distilled water; and finally carrying out elution on the template protein by using HAc-SDS, and carrying out freeze drying on the obtained product so as to obtain the fluorescent nanometer molecular imprinting biomimetic sensor.

It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to 7 is a buffer solution, especially, glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer, and the concentration of the ghrelins in the solution is from 0.03 nmol/mL to 61 μmol/mL.

The invention provides a quantum dot-antibody fluorescent probe preparation method, a quantum dot-antibody fluorescent probe, and an immunochromatography test paper strip and a preparation method thereof. The quantum dot-antibody fluorescent probe preparation method comprises: (1) adding quantum dots to a borate buffer solution to prepare a quantum dot solution; (2) adding an activator to the quantum dot solution, and activating, wherein the activator is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or a hydrochloride thereof and N-hydroxysuccinimide or a sulfide thereof, a molar ratio of the activator to the quantum dots is 5-9:1, and a molar ratio of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or the hydrochloride thereof to the N-hydroxysuccinimide or the sulfide thereof is 2-3:4-5; and 3) adding antibody to the activated quantum dot solution, and coupling to obtain the quantum dot-antibody fluorescent probe, wherein a molar ratio of the antibody to the quantum dots is 4-2:1.

An aqueous solution for cleaning and disinfecting a contact lens comprising 0.5 ppm to 5 ppm of 1,1′-hexamethylene-bis[5-(2-ethylhexyl)biguanide;

• • 0.5 ppm to 3 ppm α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl)ammonium chloride;
  • 0.005 wt. % to 0.04 wt. % hyaluronic acid;
  • a boric acid/borate buffer; and
  • a nonionic surfactant selected from poloxamer, poloxamine or any combination thereof.

The present invention relates to a stable aqueous solution (A) comprising an azo dye, a borate buffer and one or more masking agents, wherein the azo dye changes its coloration or coloration intensity in the presence of chlorine dioxide. The present invention further relates to a process for manufacturing the aqueous azo-dye solution (A), and to its use for the determination of residual chlorine dioxide in water.

Disclosed is a method for the production of two- or three-dimensional silk products, wherein native silk fibres are formed into a two- or three-dimensional silk product and the silk product formed is subjected to a degumming step wherein a borate buffer is used as degumming agent and wherein the silk product formed is preferably contacted with an aqueous ethanol buffer prior to the degumming step.

The present invention relates to a kind of synthetic method of 3-N-ethyl gentamicin C1a, the method comprises the following steps: ethylene glycol dimethyl ether, hexamethyldisilazane, concentrated sulfuric acid, 2 ", 6" ‑N,N‑Diacetylgentamycin C1a was put into a round-bottomed flask and refluxed. After the reactants were dissolved, part of the solvent was distilled off. Dichloromethane was added and stirred at 10°C, and acetaldehyde was added dropwise. After the reaction was completed, potassium borohydride and boric acid buffer were added to stir the reaction, and part of the solvent was distilled off under normal pressure. Add 10%-20% sodium hydroxide solution, heat to reflux, cool down to room temperature, and concentrate the reaction system. Desalting, the target compound 3-N-ethyl gentamycin C1a was obtained by separation.

The invention discloses a high performance liquid phase detection method of homopiperazine. The high performance liquid phase detection method comprises the steps of: diluting a fasudil hydrochlorideinjection with water and adding homopiperazine into the diluted fasudil hydrochloride injection; adding a borate buffered saline and a derivatization reagent into a dry derivatization tube; sealing the derivatization tube with a paraffin film, heating the derivatization tube, and cooling the derivatization tube to obtain a derivative sample; and acquiring a chromatogram of the derivative sample byadopting a liquid chromatograph, and measuring the content of homopiperazine. On the basis of a reversed-phase high-performance liquid phase chromatographic pre-column derivatization method-AccQ.Tagmethod developed by the Waters company, the derivatization reagent is used for adding a fluorophore onto an amino group of homopiperazine; the modified homopiperazine derivative has ultraviolet absorption, and qualitative and quantitative analysis is carried out by using high performance liquid phase chromatography. The high performance liquid phase detection method disclosed by the invention is high in precision, good in stability and good in reproducibility, enriches the method for detecting the homopiperazine content, and fills the blank that only ion chromatography can be used for liquid phase detection of the homopiperazine content.

The invention relates to a content detection method for lysine of a compound ketoacid tablet, which comprises the following steps: preparing an o-phthalaldehyde reaction liquid (OPA reagent) with the concentration of 10 mg/ml, wherein 2-3 percent (v/v) of 3-thiohydracrylic acid is contained; afterwards, mixing lysine and the reaction liquid at ratio of 1:1(v/v) in a borate buffer system with a pH valve of 10.2 plus or minus 0.1 through an automatic pre-column derivation method, and then carrying out ambient temperature reaction; and finally, adopting a high performance liquid chromatography to measure the content of the lysine at 338 nm. The method provided by the invention can effectively solve the problem that bimodality of the lysine occurs in the current OPA pre-column derivation method, improves the sample introduction precision of the lysine in the detection through the automatic pre-column derivation method, greatly shortens the detection time, and is particularly suitable for detecting the content of the lysine of amino acid samples in a laboratory.

The invention discloses a method for preparing a liquid bandage for war wounds. The method is characterized by comprising the following steps: 1, dissolving a mercapto-hyaluronic acid derivative, a tackifier, a humectant and a preservative into de-ionized water to form a component A; 2, dissolving an acrylic ester derivative and the preservative into de-ionized water, and adding a borate buffer solution to form a component B; 3, spraying the component A onto the surface of a wound, then spraying the component B to the surface of the wound, and fast generating cross-linking within 10 seconds to form the liquid bandage for the war wounds. The prepared liquid bandage for the war wounds is high in biocompatibility, free of skin irritation and cytotoxicity and applicable to relatively small war wounds such as gunshot wounds, burns and cuts. The preparation method is simple and fast, and has high practical value.

An immunohistochemical analysis and detection method based on quantum dots in the field of nanomaterials, comprising the following steps: (1) first dispersing the quantum dots in a borate buffer solution, then adding diimide sulfide and a secondary antibody, mixing , react, centrifuge, and wash to obtain the African swine fever monoclonal antibody complex labeled with quantum dots; wherein, quantum dots: diimine sulfide: the molar ratio of the secondary antibody is 60: 15: 1; or (2) first the quantum dots Disperse in a phosphate buffer solution containing 1.25% glutaraldehyde by volume, disperse, react, add a secondary antibody, react, centrifuge, and wash to obtain a quantum dot-labeled African swine fever monoclonal antibody complex; wherein, the quantum dot The molar ratio of :glutaraldehyde:secondary antibody was 60:15:1; after that, immunoreaction and observation were carried out according to the standard immunohistochemical detection method. The method of the invention directly observes with a fluorescent microscope, is simple and easy to implement, increases the stability of the fluorescent light, and improves the accuracy of analysis and the sensitivity of detection.

The invention relates to bensulfuron-methyl artificial immunogen BE-BSA, a preparation thereof and application thereof. The preparation for a structural formula comprises the following steps: (1) dissolving bensulfuron-methyl in solution of NaOH for reaction, extracting and separating the solution by chloroform, acidifying an aqueous layer, filtering the solution under reduced pressure, and drying the filtrated solution in vacuum to obtain a purified product; and (2) dissolving bensulfuron-methyl hapten, N-hydroxy succinimide (NHS) and N,N'-dicyclohexyl carbimide (DCC) in an organic solvent, stirring and reacting the mixture, and centrifugating the solution and taking supernatant to obtain active ester; and dissolving bovine serum albumin (BSA) in borate buffer solution (pH 8), adding the active ester into solution of protein under strong stirring, dialyzing the solution after reacting, packing the dialyzed product, and preserving the product at the temperature of 20 DEG C below zero. The preparation is simple and convenient, has low cost, and is easy for industrialized production; and the bensulfuron-methyl artificial immunogen BE-BSA is prepared into a bensulfuron-methyl specific antibody through immune animals for detecting trace bensulfuron-methyl in water body and soil on site.

The invention discloses a bio-enzyme immobilization method in the field of sewage treatment process, and specifically discloses a method for performing bio-enzyme immobilization through utilizing rice processing product rice bran. The method comprises the following steps: processing bio-enzyme, namely, adding hydrogen peroxide to an alkaline solution, mixing bio-enzyme with a NaOH water solution at the temperature of 30 to 35 DEG C, and then collecting supernate; adding a borate buffer solution to dissolve and precipitate; filtering to obtain alkaline protein modified enzyme liquid; mixing the alkaline protein modified enzyme liquid with rice bran in a proportion; spraying the alkaline protein modified enzyme liquid on the rice bran; and slowly drying so as to obtain the rice bran immobilization bio-enzyme. The method has the advantages of low production cost, wide raw material source and good sewage treatment effect.

The invention belongs to the field of veterinary drug residue analysis and relates to a pirlimycin residue analysis method. According to the invention, a high-performance liquid chromatograph pre-column derivatization reaction analysis is adopted for a hydrogen substitution reaction of a secondary amine compound. At the room temperature, the concentration of a derivatization reagent, chloroformic acid-9-fluorenylmethyl ester, is 10-2 mol/L, a pH value of a borate buffer solution of 0.1 mol/L is regulated to 9, the reaction is an instant reaction, as only one secondary amine is used as a single reaction site, no reaction terminator is required to be added to achieve the purpose of derivatization, and the derivation product is stable. The derivation product is subject to high performance liquid chromatograph detection, has the maximum ultraviolet strength when the ultraviolet detection wavelength is 266 nm, has the minimum detectable amount of 5 mug/L, is in linear response to the peak area within the range of 20-4000 [mu]g/L, is good in reproducibility of results, and has three concentrations, and the variable coefficient of 3 concentrations and 15 repetitions is smaller than 8%.

The invention discloses a kit for rapidly detecting ischemia modified albumin in blood. The kit comprises a detection chip and a reagent bottle filled with detection reagents, wherein the detection chip comprises a non-absorbent bottom plate and a non-absorbent cover plate; a sample cell, a mixing cell and a detection cell are sequentially arranged on the bottom plate; micro pipelines are formed between the sample cell and the mixing cell and between the mixing cell and the detection cell; a sample pad is filled in the sample cell; a cobalt standard substance is coated on the sample pad; a detection pad is filled in the detection cell; a cobalt indicator is coated on the detection pad; the cover plate is fixedly arranged above the bottom plate; a sample injection hole is formed in a position, which is positioned above the sample cell, of the cover plate; and the detection reagents refer to phosphate buffer, borate buffer or Tris-HCl buffer. According to the kit disclosed by the invention, based on the principle of an albumin cobalt binding test, sample separation and detection analysis processes are integrated into a device, so that IMA detection is more convenient.